Published in 2018 – Ann Oncol (2019) 30: 171–210.
Authors: Y.-L. Wu, D. Planchard, S. Lu, H. Sun, N. Yamamoto, D.-W. Kim, D.S.W. Tan, J.C.-H. Yang, M. Azrif, T. Mitsudomi, K. Park, R.A. Soo, J.W.C. Chang, A. Alip, S. Peters & J.-Y. Douillard
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small cell lung cancer (NSCLC) was published in 2016.
At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC in Asian patients.
These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries.
During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.